For children with Proteus syndrome, for example, Miransertib, an orally available, highly selective pan-AKT inhibitor initially developed for cancer therapeutics, can be a potential therapeutic option (Keppler-Noreuil et al. 2019; Forde et al. 2021). Here, AKT1 is linked to Proteus syndrome.